Calling all🫀AHFTC and purveyors of #critcarecards
Now that #ACC26 is over, come spend a weekend in NYC at the nation's #1 cardiac hospital to learn about what's new and exciting #CardiogenicShock#Transplant#LVAD#TAH and more! ONE month away. 🗣 Tell your friends!️
✍️Register now: https://t.co/billoxeDrX
Check out this lineup!
@ReyentovichHFMD@CarineHamo@JasonKatzMD@SVRaoMD
#ISHLT2026 #Cardiology #CardioTwitter #CardioX #MedX #FITs #WIC #HeartFailure
Thank you @ACCinTouch for the opportunity to share our work on Cardiac Amyloidosis on Septal Myectomy Specimens of Patients with HCM
🫀1.6% (9/565) had amyloidosis on pathology - TTR, AL, AA
🫀 Findings suggest coexistence of HCM + amyloidosis in some pts
@danmassera#ACC2026
Enjoyed discussing national trends in heart transplantation in adults ≥70 at #THT2026
✅ >90% of programs performed HT in ≥70 📊 Marked variability across centers & UNOS regions ❌ No correlation with center volume
Future direction: identifying which ≥70 benefit most
Persistently elevated donor-derived cell-free DNA without rejection? 👀
@GolombeckMD highlights patients with chronically elevated cfDNA of unclear etiology, raising questions about management
Prospective studies needed to define why & how to manage
#THT2026#ddcfDNA
During the Valvular Shock session 3/4 cases involved nonagenarians, reflecting shifting demographics of transcatheter valve population
Great discussion on complexity of care as patient age ⬆️ & transcatheter options expand, esp when advanced therapies aren’t an option #THT2026
Strain imaging by TTE and CMR:
🫀Detects subclinical LV dysfunction
🫀Reveals disease-specific patterns (amyloidosis, HCM, etc)
🫀Adds prognostic value across the LVEF spectrum
🫀Identifies CTRCD & informs cardioprotective therapy
Do all post PCI pts need the same obs period?
Fantastic study by Dr. Joey Lerner @nyulangone Cardiology fellow showing that individualized milestone-based observation reduces LOS!
Vutrisiran, a TTR silencer, is now FDA-approved for transthyretin cardiac amyloidosis- along w/two FDA-approved stabilizers, tafamidis and acoramidis.
There is no trial evidence to guide single vs combo therapy.
What will be your go-to regimen for ATTR-CM? Explain in comments!
1/ You are consulted overnight for a 66M found hypothermic and unresponsive in his home…
Time for #12LeadThursday 🫀⤵️
📺: https://t.co/NYxIXROhmr
🖥️: https://t.co/IZ9cZmqaKL
#GDMT use has increased over time
2/5 patients did not receive all recommended #HeartFailure medications at discharge
Reduced likelihood of receipt in:
🔸 Women
🔸 Minority patients
🔸 Urban hospitals
📎 https://t.co/ZvzJH0cHZd
#JACCHF@paheidenreich@UREssien@StanSwatMD